E

Emcure Pharmaceuticals Ltd
NSE:EMCURE

Watchlist Manager
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Watchlist
Price: 1 055.6 INR 1.98% Market Closed
Market Cap: 200B INR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one EMCURE stock under the Base Case scenario is 1 102.65 INR. Compared to the current market price of 1 055.6 INR, Emcure Pharmaceuticals Ltd is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EMCURE Relative Value
Base Case
1 102.65 INR
Undervaluation 4%
Relative Value
Price
E
Worst Case
Base Case
Best Case

Valuation Multiples

1.6
P/S
P/S
Price to Sales
1.6
vs History
50
vs Industry
58
Median 3Y
1.6
Median 5Y
1.6
Industry
2.4
Forward
2.5
More Details
20.2
P/E
P/E
Price to Earnings
20.2
vs History
50
vs Industry
24
Median 3Y
20
Median 5Y
20
Industry
20.5
Forward
28.4
More Details
22.1
P/OCF
P/OCF
Price to OCF
22.1
vs History
50
vs Industry
19
Median 3Y
22
Median 5Y
22
Industry
15.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-163.5
Median 5Y
-163.5
Industry
23.1
More Details
4.8
P/B
P/B
Price to Book Value
4.8
vs History
66
vs Industry
15
Median 3Y
6
Median 5Y
6
Industry
2
More Details
1.6
EV/S
EV/S
Enterprise Value to Sales
1.6
vs History
50
vs Industry
57
Median 3Y
1.6
Median 5Y
1.6
Industry
2.5
Forward
2.5
More Details
2.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.7
vs History
50
vs Industry
63
Median 3Y
2.6
Median 5Y
2.6
Industry
4.9
More Details
9.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.8
vs History
50
vs Industry
33
Median 3Y
9.7
Median 5Y
9.7
Industry
12.3
Forward
13.5
More Details
11.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.8
vs History
50
vs Industry
34
Median 3Y
11.8
Median 5Y
11.8
Industry
15.5
Forward
18.3
More Details
22.3
EV/OCF
EV/OCF
Enterprise Value to OCF
22.3
vs History
50
vs Industry
20
Median 3Y
22.2
Median 5Y
22.2
Industry
14.1
More Details
35.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
35.8
vs History
50
vs Industry
14
Median 3Y
35.6
Median 5Y
35.6
Industry
17.5
More Details
3.2
EV/IC
EV/IC
Enterprise Value to IC
3.2
vs History
66
vs Industry
23
Median 3Y
4
Median 5Y
4
Industry
1.8
More Details

Multiples Across Competitors

EMCURE Competitors Multiples
Emcure Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Emcure Pharmaceuticals Ltd
NSE:EMCURE
199.6B INR 1.6 20.2 9.8 11.8
US
Eli Lilly and Co
NYSE:LLY
678.4B USD 13.8 61.1 32.9 36
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
352.1B USD 3.9 16.1 11.8 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 19 12.6 14.3
CH
Roche Holding AG
SIX:ROG
202.4B CHF 3.3 24.5 9.2 10.8
CH
Novartis AG
SIX:NOVN
175B CHF 3.9 16.2 9.6 12.9
UK
AstraZeneca PLC
LSE:AZN
155.4B GBP 3.8 26.6 130.1 196.3
US
Merck & Co Inc
NYSE:MRK
184.9B USD 2.9 10.6 8 9.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
125B USD 2 15.9 7 9.8
P/E Multiple
Earnings Growth PEG
IN
E
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Average P/E: 23.3
20.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
61.1
49%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19
18%
1.1
CH
Roche Holding AG
SIX:ROG
24.5
32%
0.8
CH
Novartis AG
SIX:NOVN
16.2
17%
1
UK
AstraZeneca PLC
LSE:AZN
26.6
36%
0.7
US
Merck & Co Inc
NYSE:MRK
10.6
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
E
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Average EV/EBITDA: 394.4
9.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.9
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
11.8
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.2
6%
1.5
CH
Novartis AG
SIX:NOVN
9.6
5%
1.9
UK
AstraZeneca PLC
LSE:AZN
130.1
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7
2%
3.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
E
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Average EV/EBIT: 1 697.7
11.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.5
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.3
14%
1
CH
Roche Holding AG
SIX:ROG
10.8
6%
1.8
CH
Novartis AG
SIX:NOVN
12.9
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.3
21%
9.3
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.8
10%
1

See Also

Summary
EMCURE intrinsic value, competitors valuation, and company profile.
DCF Valuation
EMCURE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EMCURE stock valuation using valuation multiples.
Wall Street Estimates
EMCURE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EMCURE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 254,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.